Institutional members access full text with Ovid®

Share this article on:

Implications and Impact of Prior Authorization Policy on Vancomycin Use at a Tertiary Pediatric Teaching Hospital

Chan, Shannon Pharm D*; Hossain, Jobayer PhD†‡; Di Pentima, M. Cecilia MD, MPH§

The Pediatric Infectious Disease Journal: May 2015 - Volume 34 - Issue 5 - p 506–508
doi: 10.1097/INF.0000000000000615
Antimicrobial Reports

Background: We evaluated the performance of two consecutive antimicrobial stewardship interventions on vancomycin use.

Methods: Prospective audit with intervention and real time feedback to providers were implemented in April 2004. In February 2009, the institutional vancomycin policy was modified requiring preauthorization by the pediatric infectious diseases clinician on-call. Monthly vancomycin use was calculated as doses administered per 1000 patient-days.

Results: After 5 years of prospective-audit vancomycin use declined from 378 doses administered/1000 patient-days to 208 doses administered/1000 patient-days (45%). Following the implementation of preauthorization, vancomycin use decreased by an additional 16% in the subsequent 4 years. When compared with the trend of vancomycin use with prospective-audit, the trend of vancomycin use after the implementation of the restriction policy increased by 3.9 doses per month (SE: 1.51, P=0.012) during the subsequent 51 months.

Conclusions: Implementation of preauthorization didn’t significantly reduce the use of vancomycin beyond the accomplishments by prospective-audit and feedback by a team of an infectious disease pharmacist and physician.

From the *Department of Pediatrics, Alfred I. duPont Hospital for Children, Wilmington, Delaware; Nemours Biomedical Research, Wilmington, Delaware; Department of Food and Resource Economics, University of Delaware, Newark, Delaware; and §Infectious Diseases Division, Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.

Accepted for publication October 13, 2014.

The authors have no conflicts of interest or funding to disclose.

Presented in part at the 48th Annual Meeting of the Infectious Diseases Society of America, Vancouver, British Columbia, CA, October 2010 (Poster Number: 281).

Address for correspondence: M. Cecilia Di Pentima, MD, MPH, Infectious Diseases Division, Department of Pediatrics, Monroe Carell, Jr. Children’s Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1161 21st Avenue South, D-7235 MCN, Nashville, TN 37232-2581. E-mail: cecilia.dipentima@vanderbilt.edu.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.